Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,160.79
(
-0.66%
)
News Focus
News Focus
Post# of 824154
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (8) Keep Next 10 Report Keyboard Shortcuts
Replies (8) Next 10 Prev Next

HyGro

Send PM Follow Ignore
Followers 24
Posts 4180
Boards Moderated 0
Alias Born 12/18/2019

HyGro

Re: Dr Bala post# 511994

Thursday, 09/08/2022 10:58:20 AM

Thursday, September 08, 2022 10:58:20 AM

Post# of 824154
The failure rate of Phase 3 trial for approvals is ~40%. The primary reason:
"The reasons for these failures appear to be unchanged: 75 to 80% are due to problems with efficacy and/or safety."

NWBO's questionable manipulated trial data, complete confounding of the naive OS, post hoc data dredged recurrent OS arm (n=64) -- Good luck boys.
Public Reply Private Reply New Post
Keep Last Read
Replies (8) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (8) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News